Literature DB >> 24236519

Use of relative effectiveness information in reimbursement and pricing decisions in Europe.

Floortje van Nooten1, J Jaime Caro.   

Abstract

Although comparative effectiveness has received considerable attention recently - especially in the USA - it is not a new concept. In Europe, it has been applied for some time now in the pricing and reimbursement processes of many countries. Each one uses it in its own way, however, with variations in the precise definition and the role it plays in the process. It remains to be seen whether the implementation of comparative effectiveness becomes more harmonized and whether it will be integrated better with the registration process. Regardless of the extent to which it is standardized, obtaining the data will remain a substantial hurdle, both methodologically and operationally. Everyone wants comparative effectiveness information but no one knows quite how to make it happen.

Mesh:

Year:  2013        PMID: 24236519     DOI: 10.2217/cer.12.71

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  1 in total

1.  The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.

Authors:  Sarah Kleijnen; Teresa Leonardo Alves; Kim Meijboom; Iga Lipska; Anthonius De Boer; Hubertus G Leufkens; Wim G Goettsch
Journal:  Qual Life Res       Date:  2017-04-11       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.